Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.
作者信息
Ordóñez-Rubiano Maria Fernanda, Campo Isabela, Casas Mirian
机构信息
Atopic Dermatitis Clinic, Department of Dermatology, Cayre Clinical Center, Bogotá, Colombia.
Division of Dermatology, Department of Internal Medicine, Military Central Hospital, Bogotá, Colombia.
出版信息
Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5.
Abstract
摘要
相似文献
1
Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.度普利尤单抗治疗特应性皮炎：SARS-CoV-2感染患者的方案
Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5.
2
Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.度普利尤单抗治疗中度至重度特应性皮炎青少年的疗效与安全性：病例系列
Acta Derm Venereol. 2020 Jan 7;100(1):adv00014. doi: 10.2340/00015555-3368.
3
Development of alopecia in patients treated with dupilumab.使用度普利尤单抗治疗的患者中脱发的发生情况。
Dermatol Ther. 2019 May;32(3):e12869. doi: 10.1111/dth.12869. Epub 2019 Mar 18.
4
Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17?司库奇尤单抗治疗的银屑病患者发生2019冠状病毒病（COVID-19）皮疹：白细胞介素17起作用吗？
Dermatol Ther. 2020 Nov;33(6):e14011. doi: 10.1111/dth.14011. Epub 2020 Jul 27.
5
Remittive effect of Dupilumab in atopic dermatitis.度普利尤单抗在特应性皮炎中的缓解作用。
Dermatol Ther. 2018 Nov;31(6):e12711. doi: 10.1111/dth.12711. Epub 2018 Sep 25.
6
Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.度普利尤单抗治疗成人特应性皮炎期间银屑病样皮疹的发生：病例系列
Dermatol Ther. 2019 Nov;32(6):e13142. doi: 10.1111/dth.13142. Epub 2019 Nov 21.
7
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
8
Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.度普利尤单抗治疗日本特应性皮炎患者的真实世界有效性和安全性：一项单中心回顾性研究
Br J Dermatol. 2019 Nov;181(5):1083-1085. doi: 10.1111/bjd.18163. Epub 2019 Aug 22.
9
The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report.在心脏移植患者中使用选择性 Th2 阻滞剂度普利尤单抗治疗特应性皮炎：病例报告。
Dermatol Ther. 2019 Nov;32(6):e13144. doi: 10.1111/dth.13144. Epub 2019 Nov 11.
10
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.多种度普利尤单抗剂量方案在特应性皮炎初始成功治疗后的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617.
引用本文的文献
1
Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.特应性皮炎患者在 COVID-19 感染期间使用度普利尤单抗治疗是安全的：一项对 1611 例患者的系统评价和荟萃分析。
Dermatol Ther. 2022 Jun;35(6):e15476. doi: 10.1111/dth.15476. Epub 2022 Apr 7.
2
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.抗2型炎症生物疗法对COVID-19临床病程及结局的影响
J Inflamm Res. 2021 Dec 14;14:6845-6853. doi: 10.2147/JIR.S345665. eCollection 2021.
3
COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review.使用度普利尤单抗治疗的特应性皮炎患者中的COVID-19：三例病例及文献综述
Clin Cosmet Investig Dermatol. 2021 Aug 27;14:1131-1138. doi: 10.2147/CCID.S321003. eCollection 2021.
4
Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management.特应性皮炎患者皮肤科治疗专家建议：从过去展望新冠疫情下的疫苗接种管理。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3268-3275. doi: 10.1080/21645515.2021.1925502. Epub 2021 Jun 25.
5
Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis.一名感染严重特应性皮炎的HIV阳性年轻男性患者使用度普利尤单抗及感染了SARS-CoV-2，一个初步假设。
Int J Dermatol. 2021 Apr;60(4):514-515. doi: 10.1111/ijd.15499. Epub 2021 Feb 28.
6
Zoonotic coronavirus epidemics: Severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019.人畜共患冠状病毒流行：严重急性呼吸综合征、中东呼吸综合征和 2019 年冠状病毒病。
Ann Allergy Asthma Immunol. 2021 Apr;126(4):321-337. doi: 10.1016/j.anai.2020.11.021. Epub 2020 Dec 11.
本文引用的文献
1
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.在新冠疫情期间使用度普利尤单抗治疗重度特应性皮炎成年患者的管理：一项单中心真实世界经验
Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.
2
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.COVID-19 大流行期间使用全身性药物治疗银屑病和特应性皮炎的安全性考虑。
Dermatol Ther. 2020 Sep;33(5):e13687. doi: 10.1111/dth.13687. Epub 2020 Jun 19.
3
Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.针对 COVID-19 接受全身免疫抑制剂治疗的患者的循证最佳实践建议。
Clin Dermatol. 2020 Nov-Dec;38(6):775-780. doi: 10.1016/j.clindermatol.2020.05.003. Epub 2020 May 14.
4
Safety of dupilumab in atopic patients during COVID-19 outbreak.在新冠疫情期间度普利尤单抗在特应性患者中的安全性。
J Dermatolog Treat. 2022 Feb;33(1):600-601. doi: 10.1080/09546634.2020.1771257. Epub 2020 Jun 19.
5
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.正在接受度普利尤单抗治疗的患者出现新型冠状病毒2型无症状感染。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e368. doi: 10.1111/jdv.16619. Epub 2020 Jun 8.
6
Dupilumab and COVID-19: What should we expect?度普利尤单抗与 COVID-19：我们应该期待什么？
Dermatol Ther. 2020 Jul;33(4):e13502. doi: 10.1111/dth.13502. Epub 2020 May 20.
7
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis.欧洲特应性皮炎工作组关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与特应性皮炎的声明。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e241-e242. doi: 10.1111/jdv.16411.
8
Severe Adult Atopic Dermatitis: Clinical Challenges.重度成人特应性皮炎：临床挑战
Dermatitis. 2020 Jul/Aug;31(4):e48-e49. doi: 10.1097/DER.0000000000000592.
Zotero 插件